Targets › PDE3B
1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 4; Cardiovascular, Other; next expected readout Jun 2028.
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signaling. (UniProt, Q13370)
Open in Phaseline: the race on PDE3B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tenax Therapeutics | Levosimendan (TNX-103) Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator | PDE3A, PDE3B, TNNC1, TNNI3, TNNT2 | Phase 3 | Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic Shock | Jun 2028 |
Pulmonary Hypertension Associated With HFpEF (1) Pulmonary Hypertension (1) Mechanical Ventilation (1) Cardiogenic Shock (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.